Logo image of HUMA

HUMACYTE INC (HUMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HUMA - US44486Q1031 - Common Stock

1.12 USD
+0.01 (+0.9%)
Last: 12/22/2025, 9:52:00 AM
Fundamental Rating

1

Overall HUMA gets a fundamental rating of 1 out of 10. We evaluated HUMA against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of HUMA have multiple concerns. HUMA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HUMA has reported negative net income.
HUMA had a negative operating cash flow in the past year.
HUMA had negative earnings in each of the past 5 years.
In the past 5 years HUMA always reported negative operating cash flow.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

HUMA has a Return On Assets (-40.46%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -40.46%
ROE N/A
ROIC N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

HUMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

HUMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HUMA has been increased compared to 5 years ago.
Compared to 1 year ago, HUMA has an improved debt to assets ratio.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -13.02, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
HUMA has a Altman-Z score of -13.02. This is in the lower half of the industry: HUMA underperforms 77.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.02
ROIC/WACCN/A
WACCN/A
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.62 indicates that HUMA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.62, HUMA is not doing good in the industry: 81.32% of the companies in the same industry are doing better.
A Quick Ratio of 0.90 indicates that HUMA may have some problems paying its short term obligations.
With a Quick ratio value of 0.90, HUMA is not doing good in the industry: 88.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 0.9
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.84% over the past year.
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HUMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.13% yearly.
The Revenue is expected to grow by 384.64% on average over the next years. This is a very strong growth
EPS Next Y75.23%
EPS Next 2Y27.84%
EPS Next 3Y20.11%
EPS Next 5Y38.13%
Revenue Next Year1218.54%
Revenue Next 2Y946.79%
Revenue Next 3Y653.56%
Revenue Next 5Y384.64%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HUMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as HUMA's earnings are expected to grow with 20.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.84%
EPS Next 3Y20.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HUMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

HUMACYTE INC

NASDAQ:HUMA (12/22/2025, 9:52:00 AM)

1.12

+0.01 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners24.89%
Inst Owner Change-19.74%
Ins Owners5.98%
Ins Owner Change2.24%
Market Cap209.74M
Revenue(TTM)1.57M
Net Income(TTM)-37.03M
Analysts81.54
Price Target8.01 (615.18%)
Short Float %22.31%
Short Ratio5.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.83%
Min EPS beat(2)-45.54%
Max EPS beat(2)31.89%
EPS beat(4)3
Avg EPS beat(4)67.02%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)14.72%
EPS beat(12)7
Avg EPS beat(12)11.48%
EPS beat(16)10
Avg EPS beat(16)42.93%
Revenue beat(2)0
Avg Revenue beat(2)-45.27%
Min Revenue beat(2)-70.58%
Max Revenue beat(2)-19.96%
Revenue beat(4)0
Avg Revenue beat(4)-55.97%
Min Revenue beat(4)-100%
Max Revenue beat(4)-19.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)28.8%
EPS NQ rev (1m)4.81%
EPS NQ rev (3m)12.22%
EPS NY rev (1m)9.56%
EPS NY rev (3m)-23.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-36.72%
Revenue NY rev (1m)-22.3%
Revenue NY rev (3m)-24.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 133.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.01
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.46%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.31%
Cap/Sales 57.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 0.9
Altman-Z -13.02
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.4%
Cap/Depr(5y)14.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y75.23%
EPS Next 2Y27.84%
EPS Next 3Y20.11%
EPS Next 5Y38.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1218.54%
Revenue Next 2Y946.79%
Revenue Next 3Y653.56%
Revenue Next 5Y384.64%
EBIT growth 1Y6.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.92%
EBIT Next 3Y28.21%
EBIT Next 5Y25.39%
FCF growth 1Y-39.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.48%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 1 / 10 to HUMA.


What is the valuation status of HUMACYTE INC (HUMA) stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


Can you provide the profitability details for HUMACYTE INC?

HUMACYTE INC (HUMA) has a profitability rating of 0 / 10.


Can you provide the financial health for HUMA stock?

The financial health rating of HUMACYTE INC (HUMA) is 1 / 10.